Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
July 07, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
XBIO
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
June 02, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
April 27, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
March 23, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
September 09, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
July 28, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
July 26, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
May 12, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
May 10, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit